enGene Holdings Inc. (ENGNW)

NASDAQ: ENGNW · Real-Time Price · USD · Warrants
2.790
-0.110 (-3.79%)
At close: Jan 9, 2026, 4:00 PM EST
2.600
-0.190 (-6.81%)
After-hours: Jan 9, 2026, 4:00 PM EST
-3.79%
Market Cap590.13M
Revenue (ttm)n/a
Net Income (ttm)-117.30M
Shares Out 66.98M
EPS (ttm)-2.29
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume47,685
Open2.750
Previous Close2.900
Day's Range2.750 - 2.820
52-Week Range0.510 - 3.800
Beta-0.28
Analystsn/a
Price Targetn/a
Earnings DateDec 22, 2025

About ENGNW

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Ronald H. Cooper
Employees 82
Stock Exchange NASDAQ
Ticker Symbol ENGNW
Full Company Profile

News

There is no news available yet.